Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

NCT02256709 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2014-10-06

No results posted yet for this study

Summary

Safety, tolerability and pharmacokinetics (including comparisons of different formulations and investigation of food effect)

Conditions

  • Healthy

Interventions

DRUG

BIBP 5371 CL tablet

single rising daily doses

DRUG

BIBP 5371 CL solution

OTHER

High fat, high caloric breakfast

DRUG

Placebo tablet

DRUG

BIBP 5371 CL tablet high dose

DRUG

Placebo drinking solution

DRUG

BIBP 5371 CL tablet low dose

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2004-08-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02256709 on ClinicalTrials.gov